Varian Uses AI to Usher in New Era of Cancer Therapy at ASTRO

Four years ago, Varian’s Applied Research Team, a group separate from its research and development unit, began looking at how to incorporate artificial intelligence into cancer therapy. The team’s hard work has resulted in the development of Ethos, an AI-driven holistic solution designed to increase the efficiency of radiotherapy. MD+DI spoke with Chris Toth, president of Varian Oncology Systems ahead of Ethos’ launch at the American Society for Radiation Oncology [ASTRO] annual meeting in Chicago held this week. Ethos is an Adaptive Intelligence solution. Toth told MD+DI, “Ethos therapy is the culmination of decades of the pursuit of how to personalize and adapt radiation therapy to every patient; everyday; in their anatomy; in any deprivation of the tumor or associated tissue, so that we can absolutely achieve what we want to in the context of maximizing the dose to the tumor and missing the healthy tissue.” The Palo Alto, CA-based company’s technology has CE mark and not yet been cleared in the U.S. The company said FDA clearance is pending. Ethos solves for an issue that has plagued cancer therapy treatments for years. “The challenge remains that patients get their treatments over a certain number of visits,” Toth said. “It could be five … 10 … 40 different visi...
Source: MDDI - Category: Medical Devices Authors: Tags: Imaging Source Type: news